Atorvastatin Relieves Cognitive Disorder After Sepsis Through Reverting Inflammatory Cytokines, Oxidative Stress, and Neuronal Apoptosis in Hippocampus
This present research work reports the possible effects and the underlying mechanism of atorvastatin on survival rate and cognitive disorders after sepsis. Sepsis is a life-threatening dysfunction that arises when the body’s response to infection causes injury to its own tissues and organs. Diffuse sepsis was induced by cecal ligation and puncture surgery (CLP) in ICR mice. 0.2 mg/kg body weight of atorvastatin was administrated intraperitoneally at 12 h before surgery. The survival of mice was calculated 24 h, 48 h, 72 h, and 96 h after CLP surgery. Two weeks later, open-field test and Morris water maze test were conducted to evaluate the protective effect of atorvastatin. Inflammatory cytokines in plasma, oxidative stress parameters, number of astrocytes, and neuronal cell deaths in the CA3 region of the hippocampus were examined using enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry. The results indicate that pretreatment with atorvastatin can increase survival percentage and improve cognitive function. Atorvastatin reversed all these alterations in parallel with a decrease in circulating levels of cytokines (IL-1β, IL-4, IL-6, and TNF-α) in plasma, inhibited the activities of oxidative stress parameters (lower TBARS levels, ratio of GSH/GSSH, and activities of SOD and CAT), enhanced the activity of citrate synthase in brain, and reduced the number of astrocytes and neuronal cell deaths in CA3 region of hippocampus. Overall, our results indicated that atorvastatin exhibited protective effects on survival rate and cognitive disorders after sepsis by inhibiting the release of inflammatory cytokines, oxidative stress, and neuronal apoptosis in brain tissue.
KeywordsAtorvastatin Sepsis Inflammation Oxidative stress Apoptosis
This work was supported by the Jiangsu province natural science foundation of China (BK20151204).
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no competing interests.
- Calisto KL, Carvalho Bde M, Ropelle ER, Mittestainer FC, Camacho AC, Guadagnini D, Carvalheira JB, Saad MJ (2010) Atorvastatin improves survival in septic rats: effect on tissue inflammatory pathway and on insulin signaling. PLoS ONE 5(12):e14232. https://doi.org/10.1371/journal.pone.0014232 CrossRefPubMedPubMedCentralGoogle Scholar
- Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R (2012) Surviving Sepsis Campaign Guidelines Committee including The Pediatric S (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Intensive Care Med 39(2):165–228. https://doi.org/10.1007/s00134-012-2769-8 CrossRefGoogle Scholar
- dos Santos RS, Donadio MV, da Silva GV, Blattner CN, Melo DA, Nunes FB, Dias FS, Squizani ED, Pedrazza L, Gadegast I, de Oliveira JR (2014) Immediate effects of chest physiotherapy on hemodynamic, metabolic, and oxidative stress parameters in subjects with septic shock. Respir Care 59(9):1398–1403. https://doi.org/10.4187/respcare.02859 CrossRefPubMedGoogle Scholar
- Kandasamy K, Prawez S, Choudhury S, More AS, Ahanger AA, Singh TU, Parida S, Mishra SK (2011) Atorvastatin prevents vascular hyporeactivity to norepinephrine in sepsis: role of nitric oxide and alpha(1)-adrenoceptor mRNA expression. Shock 36(1):76–82. https://doi.org/10.1097/SHK.0b013e31821a4002 CrossRefPubMedGoogle Scholar
- Ma M, Uekawa K, Hasegawa Y, Nakagawa T, Katayama T, Sueta D et al (2013) Pretreatment with rosuvastatin protects against focal cerebral ischemia/reperfusion injury in rats through attenuation of oxidative stress and inflammation. Brain Res 1519:87–94. https://doi.org/10.1016/j.brainres.2013.04.040 CrossRefPubMedGoogle Scholar
- Merx MW, Liehn EA, Janssens U, Lutticken R, Schrader J, Hanrath P, Weber C (2004) HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 109(21):2560–2565. https://doi.org/10.1161/01.CIR.0000129774.09737.5B CrossRefPubMedGoogle Scholar
- Reis PA, Alexandre PC, D’Avila JC, Siqueira LD, Antunes B, Estato V, Tibirica EV, Verdonk F, Sharshar T, Chretien F, Castro-Faria-Neto HC, Bozza FA (2017) Statins prevent cognitive impairment after sepsis by reverting neuroinflammation, and microcirculatory/endothelial dysfunction. Brain Behav Immun 60:293–303. https://doi.org/10.1016/j.bbi.2016.11.006 CrossRefPubMedGoogle Scholar
- Sierra S, Ramos MC, Molina P, Esteo C, Vazquez JA, Burgos JS (2011) Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis 23(2):307–318. https://doi.org/10.3233/JAD-2010-101179 CrossRefPubMedGoogle Scholar
- Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315(8):801–810. https://doi.org/10.1001/jama.2016.0287 CrossRefPubMedPubMedCentralGoogle Scholar
- Thangamalai R, Kandasamy K, Sukumarn SV, Reddy N, Singh V, Choudhury S, Parida S, Singh TU, Boobalan R, Mishra SK (2014) Atorvastatin prevents sepsis-induced downregulation of myocardial beta1-adrenoceptors and decreased cAMP response in mice. Shock 41(5):406–412. https://doi.org/10.1097/SHK.0000000000000138 CrossRefPubMedGoogle Scholar